Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACEPHEN vs FORANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Enhances GABA-A receptor activity and inhibits glutamate receptors, leading to neuronal hyperpolarization and anesthesia.
Mild to moderate pain,Fever
Induction and maintenance of general anesthesia,Sedation for mechanical ventilation in intensive care
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Induction: 0.5-3% inspired; Maintenance: 0.5-2% inspired.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Context-sensitive half-life: 2-5 minutes after short exposure; prolonged to 30-60 minutes after prolonged administration due to accumulation in fat and muscle. Terminal elimination half-life: 0.5-1 hour.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily hepatic via CYP2E1; also undergoes glucuronidation and defluorination.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Primarily exhaled unchanged via lungs (>95%); <5% metabolized in liver to fluoride ions and other metabolites, which are excreted renally.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
~40% bound to plasma proteins (mainly albumin).
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Vd: 1.5-2.0 L/kg, reflecting distribution to highly perfused tissues (brain, heart, liver, kidneys) and subsequent redistribution to muscle and fat.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
100% via inhalation.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
No adjustment required.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Use with caution; reduce dose in severe hepatic impairment (Child-Pugh C).
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Induction: 1-4% inspired; Maintenance: 0.5-2% inspired.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Reduce inspired concentrations by 25-50% due to increased sensitivity.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
None
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Risk of malignant hyperthermia,Respiratory depression,Hypotension,Hepatotoxicity with repeated use or in susceptible patients,Nephrotoxicity due to fluoride ions
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Known hypersensitivity to isoflurane or other halogenated agents,Known or suspected genetic susceptibility to malignant hyperthermia
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
No specific food interactions are documented for isoflurane. However, patients should follow standard preoperative fasting guidelines (e.g., NPO for 8 hours prior to elective surgery) to reduce aspiration risk during anesthesia.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
FORANE (isoflurane) is classified as FDA Category C. In first trimester, animal studies show fetal malformations at high doses; human data insufficient. Second and third trimesters: known to cause dose-dependent maternal hypotension and uterine relaxation, which may reduce placental perfusion; use only if clearly needed.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Isoflurane is excreted into breast milk in minimal amounts; M/P ratio is approximately 0.85. After inhalational anesthesia, the concentration in milk is low and rapidly cleared. The American Academy of Pediatrics considers it compatible with breastfeeding. However, it is recommended to discard milk for 24 hours post-procedure due to sedation and potential metabolites.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
No specific dose adjustment is required for pregnancy, but due to increased volume of distribution and decreased protein binding, a slightly lower dose may achieve desired anesthetic depth. Maintenance of uterine perfusion pressure is critical; avoid hypotension. The minimum alveolar concentration (MAC) is decreased by approximately 25% in pregnancy.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
FORANE (isoflurane) is a potent inhalational anesthetic with rapid onset and offset due to low blood-gas solubility. It causes dose-dependent respiratory depression and hypotension via peripheral vasodilation. Monitor end-tidal CO2 and arterial blood pressure closely. Avoid in patients with known or suspected malignant hyperthermia susceptibility. Use a calibrated vaporizer to deliver precise concentrations (1-3% for induction, 0.5-2% for maintenance).
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
This medication is for hospital use only and will be administered by an anesthesia provider.,You may experience drowsiness, dizziness, or confusion after waking from anesthesia.,Do not drive or operate machinery for at least 24 hours after receiving this drug.,Inform your doctor if you have a personal or family history of malignant hyperthermia.,Report any muscle rigidity, fever, or dark urine to your healthcare provider immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACEPHEN vs FORANE, answered by our medical review team.
ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. FORANE is a Inhalational Anesthetic that works by Enhances GABA-A receptor activity and inhibits glutamate receptors, leading to neuronal hyperpolarization and anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACEPHEN and FORANE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. The standard adult dose of FORANE is: Induction: 0.5-3% inspired; Maintenance: 0.5-2% inspired.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACEPHEN and FORANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. FORANE is classified as Category C. FORANE (isoflurane) is classified as FDA Category C. In first trimester, animal studies show fetal malformations at high doses; human data insufficient. Second and third trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.